US CRISPR Market (2025-2030)
The US CRISPR Market was valued at $1023.8 Million in 2025 and projected to reach to $1726.2 Million by 2030, representing a compound annual growth rate of 11.0%. The US CRISPR market is poised for significant expansion through 2030, driven by increasing clinical trial approvals, growing investment in gene-editing technologies, and rising prevalence of genetic disorders.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US CRISPR Market Trends and Insights
- The US leads global CRISPR adoption due to advanced healthcare infrastructure, substantial R&D investment, and a favorable regulatory environment that accelerates gene-editing therapies to market.
- Strong venture capital funding and partnerships between biotech firms and academic institutions position the US as the epicenter of CRISPR innovation. Driving this expansion, the US benefits from increasing clinical trial activity, growing patient awareness, and rising prevalence of genetic disorders.
- The US regulatory pathway, particularly FDA guidance on gene therapies, enables faster commercialization compared to other regions.
- Major pharmaceutical and biotechnology companies in the US are investing heavily in CRISPR-based therapeutics, creating a competitive landscape that fuels market growth. By 2030, the US CRISPR market will reflect broader adoption across oncology, rare genetic diseases, and immunotherapy applications.
- The US market's 11.0% compound annual growth rate underscores sustained confidence in CRISPR's therapeutic potential and commercial viability within the American healthcare system..
Key Market Statistics
- CAGR (2025-2030) 11.0% CAGR
- Market Size, 2025 ~USD 1023.8 Million
- Forecast, 2030 ~USD 1726.2 Million
- Country US
US CRISPR Market Overview
Market Valuation Growth :
The US CRISPR market is valued at $1,023.8 million in 2025 and is projected to reach $1,726.2 million by 2030, representing a robust 11% CAGR over the forecast period.
Regulatory Leadership :
The US maintains a favorable regulatory environment through the FDA's accelerated approval pathways, enabling faster commercialization of CRISPR-based gene-editing therapies compared to other global markets.
R&D Investment Hub :
Substantial venture capital funding and strategic partnerships between biotech companies and academic institutions position the US as the global leader in CRISPR research and development initiatives.
Healthcare Infrastructure Advantage :
Advanced healthcare infrastructure, high healthcare spending, and strong reimbursement mechanisms in the US support widespread adoption and commercialization of CRISPR-based therapeutic solutions.
US CRISPR Market Dynamics
- Major pharmaceutical and biotech companies are accelerating their CRISPR pipelines, with several therapies expected to receive regulatory approval in the coming years.
- The US market benefits from robust intellectual property protections and a mature healthcare ecosystem that facilitates rapid adoption of innovative treatments.
- Continued government support for precision medicine initiatives and expanding insurance coverage for gene therapies will further accelerate market penetration across diverse patient populations and therapeutic areas..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- The US CRISPR market is valued at $1,023.8 million in 2025 and is projected to reach $1,726.2 million by 2030, representing an 11.0% CAGR.
- The US dominates global CRISPR development due to advanced infrastructure, substantial R&D funding, and FDA-friendly regulatory pathways that expedite therapy commercialization.
- Clinical trial expansion and rising patient awareness of genetic disorder treatments are primary growth catalysts driving US market expansion through 2030.
- The US competitive landscape features major pharmaceutical companies and biotech startups investing heavily in CRISPR therapeutics across oncology, rare diseases, and immunotherapy.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
US CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
US: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 96 | 112.8 | 125.4 | 140.1 | 156.3 | 174.5 | 195.1 | 218.1 | 11.7 |
| OTHER END USERS | 103.3 | 120.4 | 132.8 | 147.1 | 162.7 | 180.1 | 199.7 | 221.3 | 10.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 125.4 | 147.8 | 164.9 | 184.9 | 206.9 | 231.6 | 259.8 | 291.4 | 12.1 |
| TOTAL | 324.7 | 381 | 423.1 | 472.1 | 525.9 | 586.2 | 654.5 | 730.8 | 11.5 |
US: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 246.3 | 249.9 | 276 | 306.3 | 339.3 | 376.1 | 417.6 | 463.7 | 10.9 |
| OTHER END USERS | 323.7 | 327.9 | 361.7 | 400.6 | 443.2 | 490.5 | 543.8 | 602.8 | 10.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 342.2 | 348.4 | 386.1 | 429.9 | 477.9 | 531.5 | 592.1 | 659.7 | 11.3 |
| TOTAL | 912.3 | 926.3 | 1023.8 | 1136.8 | 1260.3 | 1398 | 1553.5 | 1726.2 | 11 |
Target Audience
- Biotech & Pharmaceutical Companies : US-based and international biotech firms need market intelligence to guide R&D investments, clinical trial planning, and commercialization strategies for CRISPR-based therapeutics in the American market.
- Venture Capital & Private Equity Firms : Investment firms require detailed US market data, growth projections, and competitive analysis to evaluate CRISPR company valuations, funding opportunities, and portfolio performance metrics.
- Healthcare Providers & Hospital Systems : US hospitals and healthcare networks need insights on CRISPR therapy availability, reimbursement status, and patient eligibility to plan service offerings and budget allocations.
- Regulatory & Policy Advisors : Government agencies, policy consultants, and regulatory bodies require US market data to inform healthcare policy, reimbursement decisions, and precision medicine initiatives.
- Market Research & Strategy Consultants : Consulting firms and research organizations need comprehensive US CRISPR market data to support client advisory services, competitive benchmarking, and strategic planning engagements.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation data ($1,023.8M in 2025) and verified 5-year forecasts to support investment decisions, business planning, and competitive positioning in the American CRISPR sector.
- Regulatory & Approval Insights : Understand the US FDA approval landscape, accelerated pathways, and regulatory timelines specific to CRISPR therapies, enabling faster go-to-market strategies for biotech companies and investors.
- Competitive Landscape Analysis : Identify leading US-based CRISPR companies, emerging players, partnership opportunities, and market consolidation trends to inform strategic partnerships and M&A decisions.
- Reimbursement & Pricing Strategy : Access detailed US healthcare reimbursement frameworks, insurance coverage trends, and pricing benchmarks for CRISPR therapies to optimize commercial strategies and revenue projections.
- Investment & Funding Opportunities : Leverage comprehensive data on US venture capital flows, government grants, and funding trends in CRISPR to identify investment opportunities and assess market attractiveness for stakeholders.
Frequently asked questions
What is the current size of the US CRISPR market in 2025?
The US CRISPR market is valued at $1,023.8 million in 2025, reflecting strong adoption of gene-editing technologies across therapeutic development and clinical applications.
What is the projected size of the US CRISPR market by 2030?
The US CRISPR market is forecast to reach $1,726.2 million by 2030, growing at an 11.0% compound annual growth rate from 2025 to 2030.
What factors are driving growth in the US CRISPR market?
Key growth drivers in the US include increased clinical trial activity, FDA regulatory support for gene therapies, rising prevalence of genetic disorders, and substantial venture capital investment in CRISPR-based therapeutics.
Which therapeutic areas are leading CRISPR adoption in the US?
The US CRISPR market is expanding across oncology, rare genetic diseases, and immunotherapy applications, with significant clinical development in sickle cell disease and beta-thalassemia treatments.
How does the US CRISPR market compare to global trends?
The US CRISPR market grows at 11.0% CAGR, slightly below the global rate of 11.2%, but the US maintains the largest absolute market size and leads in commercialization due to regulatory advantages and R&D infrastructure.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
- Rest Of Europe CRISPR Market
- Rest Of Asia Pacific CRISPR Market
- Rest Of Latin America CRISPR Market
- Canada CRISPR Market
- Germany CRISPR Market
- UK CRISPR Market
- France CRISPR Market
- Italy CRISPR Market
- Spain CRISPR Market
- China CRISPR Market
- Japan CRISPR Market
- India CRISPR Market
- Brazil CRISPR Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report